GO
Loading...

Enter multiple symbols separated by commas

Gilead Sciences Inc

More

  • Medical cost inflation hits 8-year high, but why? Friday, 22 May 2015 | 4:40 PM ET
    Doctors medicine surgeons

    Economists can't figure out what's behind a major spike in medical care prices seen in April, or whether it will last.

  • May 20- U.S. healthcare conglomerate Johnson& Johnson said on Wednesday it expects to submit more than 10 new medicines with annual revenue potential of at least $1 billion each to regulators by 2019, and is testing dozens of new uses for existing medicines. J&J said it would file for approval of daratumumab for the blood cancer multiple myeloma in the United...

  • NEW YORK, May 20- A U.S. group is trying to block patents in five countries for Gilead Sciences Inc's costly hepatitis C drug Sovaldi, in a bid to give almost 60 million afflicted people access to cheaper generic versions. In Argentina, Brazil, China, Russia and Ukraine, challenges have been filed against Gilead's patents or patent applications, the New York- based...

  • 19)@ (Corrects paragraphs 2 and 3 to say J&J's $1.1 billion potential payments include equity investment of $225 million and are not in addition to the $1.1 billion). May 19 (Reuters)- Achillion Pharmaceuticals Inc said it will collaborate with Johnson& Johnson to develop and market its hepatitis C drugs including an oral regimen that could work on all genotypes and...

  • NEW YORK, May 20- U.S. healthcare conglomerate Johnson& Johnson said on Wednesday it expects to submit more than 10 new medicines with annual revenue potential of at least $1 billion each to regulators by 2019, and is testing dozens of new uses for existing medicines. J&J said it would file for approval of the experimental drug daratumumab for the blood cancer...

  • May 19- Achillion Pharmaceuticals Inc said it will collaborate with Johnson& Johnson to develop and market its hepatitis C drugs including an oral regimen that could work on all genotypes and shorten treatment time. Johnson& Johnson will also invest $225 million in Achillion in return for about 18.4 million unregistered shares at $12.25 per share.

  • Here's how to play weak Q2 earnings season Monday, 18 May 2015 | 7:39 AM ET
    Delta Airlines planes sit at Terminal 4 at John F. Kennedy Airport in New York.

    Negative revenue growth will continue to dog investors in Q2 and Q3, analyst Mike Thompson says. Here's what to do about it.

  • 500,000 Americans spend $50K on medicine each year Wednesday, 13 May 2015 | 12:01 AM ET
    Prescription drugs

    More than half a million Americans have annual prescription drug costs of more than $50,000.

  • These biotech names are ripe for mergers: Analysts Sunday, 10 May 2015 | 11:00 AM ET
    Biotech pharmaceuticals

    The next takeout target in biotech? Here are three eligible candidates

  • Smart or suckers? Buybacks to hit $1 trillion Friday, 8 May 2015 | 12:18 PM ET
    GE General Electric

    In April, U.S companies said they would buy back $141 billion worth of their own stock, the largest repurchase authorization ever.

  • Cramer: A triple threat triggering your portfolio Monday, 4 May 2015 | 6:13 PM ET
    Warren Buffett, chairman of Berkshire Hathaway Inc.

    Jim Cramer sees there was a triple-threat combination of events out there that is bringing the market higher. Could it be impacting your portfolio?

  • Can a stock market killed in 1959 return to life? Friday, 1 May 2015 | 9:57 AM ET
    Tourists take in the sites from a tour bus in Havana, Feb. 28, 2015.

    With the diplomatic thaw between Cuba and the US, a more open Cuba could create a stock market that rewards investors.

  • Early movers: NWL, MCO, VFC, CVS, LNKD & more Friday, 1 May 2015 | 7:53 AM ET

    Some of the names on the move ahead of the open.

  • Thursday's after-hours buzz: LinkedIn, AIG & more Thursday, 30 Apr 2015 | 5:35 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Take a look at some of Thursday's after-hours buzz: LinkedIn, AIG & more

  • LOS ANGELES, April 30- Gilead Sciences Inc said on Thursday its quarterly net profit nearly doubled, driven by sales of its novel hepatitis C drugs, as it topped Wall Street estimates. Excluding one-time items, Gilead earned $2.94 per share in the first quarter, outpacing the average Wall Street estimate of $2.32, according to Thomson Reuters I/B/E/S.

  • Trades to go as April winds down Thursday, 30 Apr 2015 | 2:12 PM ET

    The "Halftime Report" traders give their trades for the second half.

  • Street picks: 10 stocks ready to pop Thursday, 30 Apr 2015 | 7:00 AM ET

    More than half of the S&P 500 is projected to rise by 8 percent in 12 months, according to analysts. Here are the stocks that could rise the most.

  • Market digs for next clue for data dependent Fed Thursday, 30 Apr 2015 | 6:03 AM ET
    The Marriner S. Eccles Federal Reserve Building in Washington.

    The markets quickly shifted focus from the Fed meeting to the upcoming April jobs report.

  • What you need to know for Thursday trading Wednesday, 29 Apr 2015 | 5:33 PM ET
    The Marriner S. Eccles Federal Reserve Building in Washington.

    The markets quickly shifted focus from the Fed meeting to the upcoming April jobs report.

  • April 29- Pharmacy benefit manager Express Scripts Holding Co, which has aggressively negotiated lower costs of new hepatitis C drugs, on Wednesday said a new "focus area" will be subduing costs of a growing wave of pricey biotech cancer drugs. "This is going to be a much slower and much bigger effort over time than what you saw for hepatitis," Steve Miller, chief...